Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST)
Market Cap | 1.047 Billion | Shares Outstanding | 75.947 Million | Avg 30-day Volume | 577.196 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.37 |
Price to Revenue | 9.2389 | Debt to Equity | 0.0 | EBITDA | -181.273 Million |
Price to Book Value | 2.9025 | Operating Margin | -136.7639 | Enterprise Value | 847.817 Million |
Current Ratio | 5.674 | EPS Growth | 0.557 | Quick Ratio | 5.018 |
1 Yr BETA | 1.1215 | 52-week High/Low | 22.76 / 10.14 | Profit Margin | -131.3834 |
Operating Cash Flow Growth | 32.7532 | Altman Z-Score | 3.7856 | Free Cash Flow to Firm | -149.858 Million |
Earnings Report | 2023-08-03 |
Please sign in first
11 Thousand total shares from 1 transactions
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
11,000 | 2023-05-10 | 3 | |
HOERTER STEVEN L. PRESIDENT AND CEO |
|
0 | 2023-03-21 | 2 |
|
22,145,707 | 2023-02-28 | 2 | |
SHERMAN MATTHEW L EVP & CHIEF MEDICAL OFFICER |
|
88,145 | 2023-02-15 | 4 |
KELLY THOMAS PATRICK CHIEF FINANCIAL OFFICER |
|
58,795 | 2023-02-15 | 3 |
FLYNN DANIEL LEE CHIEF SCIENTIFIC OFFICER |
|
440,451 | 2023-02-15 | 3 |
MARTIN DANIEL C. CHIEF COMMERCIAL OFFICER |
|
58,381 | 2023-02-15 | 3 |
PITMAN JAMA SEE REMARKS |
|
45,050 | 2023-02-15 | 3 |
|
3,269 | 2023-01-17 | 2 | |
|
3,269 | 2023-01-17 | 2 | |
|
3,269 | 2023-01-17 | 2 | |
|
3,269 | 2023-01-17 | 2 | |
|
18,500 | 2022-06-23 | 1 | |
|
18,500 | 2022-06-23 | 1 | |
|
18,500 | 2022-06-23 | 1 | |
|
193,752 | 2021-05-03 | 0 | |
MORL CHRISTOPHER JOHN CHIEF BUSINESS OFFICER |
|
0 | 2020-01-15 | 0 |
NEW LEAF VENTURE MANAGEMENT III, L.L.C. NEW LEAF BIOPHARMA OPPORTUNITIES I, L.P. |
|
No longer subject to file | 2019-08-15 | 0 |
|
0 | 2019-06-11 | 0 | |
RUDDY STEPHEN B. CHIEF TECHNICAL OFFICER |
|
0 | 2019-01-30 | 0 |
|
0 | 2018-05-17 | 0 | |
ROSEN OLIVER CHIEF MEDICAL OFFICER |
|
0 | 2017-10-02 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-05-12 16:05:10 -0400 | 2023-05-10 | P | 11,000 | $13.86 | a | 11,000 | direct | -3.7975 | 0.7032 | 3.9381 | 5 | -3.7975 | 2 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 22:15:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 21:45:05 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 21:15:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 20:45:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 20:15:05 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 19:45:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 19:15:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 18:45:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 18:15:03 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 17:45:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 17:15:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 16:45:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 16:15:03 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 15:45:03 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 15:15:03 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 14:45:05 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 14:15:04 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 13:45:05 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 13:15:03 UTC | 4.82 | 0.25 | 2000000 |
DECIPHERA PHARMACEUTICALS IN DCPH | 2023-05-29 12:45:03 UTC | 4.82 | 0.25 | 2000000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Trust for Professional Managers- Convergence Market Neutral Fund | DCPH | -1514.0 shares, $-68145.14 | 2020-08-31 | N-PORT |
FundVantage Trust- Gotham Enhanced Index Plus Fund | DCPH | -126.0 shares, $-5187.42 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | DCPH | -49.0 shares, $-2017.33 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Master Neutral Fund | DCPH | -18.0 shares, $-923.4 | 2020-09-30 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | DCPH | -106.0 shares, $-4364.02 | 2020-03-31 | N-PORT |